Clinical Trial Update: Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting on the combination of Ofatumumab and Ibrutinib with allogeneic bone marrow transplant or consolidation in high-risk chronic lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ibrutinib (Imbruvica) (Ibrutinib)
• Ofatumumab (Arzerra) (Ofatumumab)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Leukemia, Lymphoblastic, Chronic | Phase 2 | Status: COMPLETED